Details of the Drug

General Information of Drug (ID: DMXZRW0)

• Drug Name: DTI-015
• Synonyms: Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Brain cancer	2A00	Approved	[1]
Glioblastoma of brain	2A00.00	Approved	[2]
Liver cancer	2C12	Approved	[3]
Malignant glioma	2A00.0	Approved	[4]
Plasma cell myeloma	2A83.1	Approved	[5]
Classic Hodgkin lymphoma	N.A.	Investigative	[5]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 214.05
  Logarithm of the Partition Coefficient (xlogp); 1.5
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
  Bioavailability: The bioavailability of drug is 5-28% []
  Clearance: The drug present in the plasma can be removed from the body at the rate of 78 mL/min/kg [7]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 15 - 30 minutes [7]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.5498 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.23% [7]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [7]
  Water Solubility: The ability of drug to dissolve in water is measured as 3.8 mg/mL [6]
• Chemical Identifiers:
  Formula: C5H9Cl2N3O2
  IUPAC Name: 1,3-bis(2-chloroethyl)-1-nitrosourea
  Canonical SMILES: C(CCl)NC(=O)N(CCCl)N=O
  InChI: InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)
  InChIKey: DLGOEMSEDOSKAD-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2578
  ChEBI ID: CHEBI:3423
  CAS Number: 154-93-8
  DrugBank ID: DB00262
  TTD ID: D01OXI
  INTEDE ID: DR0278
  ACDINA ID: D00918
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Binder	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Glutathione S-transferase alpha-1 (GSTA1)	DE4ZHS1	GSTA1_HUMAN	Substrate	[9]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
14-3-3 protein eta	OTP8NJFJ	1433F_HUMAN	Gene/Protein Processing	[11]
2-hydroxyacylsphingosine 1-beta-galactosyltransferase	OT17ST61	CGT_HUMAN	Gene/Protein Processing	[11]
3-mercaptopyruvate sulfurtransferase (MPST)	OTCDPH5D	THTM_HUMAN	Drug Response	[12]
5'-AMP-activated protein kinase catalytic subunit alpha-2 (PRKAA2)	OTU1KZPV	AAPK2_HUMAN	Drug Response	[12]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2)	OTG7NW98	F262_HUMAN	Gene/Protein Processing	[11]
A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4)	OT4CA13K	ATS4_HUMAN	Gene/Protein Processing	[11]
Acetylcholine receptor subunit gamma (CHRNG)	OTXC2UR7	ACHG_HUMAN	Gene/Protein Processing	[11]
Actin, alpha cardiac muscle 1 (ACTC1)	OTJU04B1	ACTC_HUMAN	Gene/Protein Processing	[11]
Actin, gamma-enteric smooth muscle (ACTG2)	OTRDWUO0	ACTH_HUMAN	Gene/Protein Processing	[11]
Actin-binding protein WASF2	OTRT4F55	WASF2_HUMAN	Drug Response	[12]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from DTI-015 (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[13]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Thioguanine.	Acute myeloid leukaemia [2A60]	[14]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[15]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of DTI-015 and Roflumilast.	Asthma [CA23]	[16]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[17]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[17]
ABT-492	DMJFD2I	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[17]
Levofloxacin	DMS60RB	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of DTI-015 and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[18]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[17]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Cannabidiol.	Epileptic encephalopathy [8A62]	[16]
Digoxin	DMQCTIH	Moderate	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Digoxin.	Heart failure [BD10-BD1Z]	[19]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[20]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of DTI-015 and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[22]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of DTI-015 and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[23]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of DTI-015 and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[24]
Penbutolol	DM4ES8F	Minor	Increased plasma concentration of DTI-015 and Penbutolol due to competitive binding of plasma proteins.	Hypertension [BA00-BA04]	[25]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Methotrexate.	Leukaemia [2A60-2B33]	[16]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of DTI-015 and Denosumab.	Low bone mass disorder [FB83]	[26]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[27]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Idelalisib.	Mature B-cell leukaemia [2A82]	[28]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Clofarabine.	Mature B-cell lymphoma [2A85]	[29]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of DTI-015 and Thalidomide.	Multiple myeloma [2A83]	[30]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of DTI-015 and Tecfidera.	Multiple sclerosis [8A40]	[31]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of DTI-015 and Siponimod.	Multiple sclerosis [8A40]	[13]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of DTI-015 and Fingolimod.	Multiple sclerosis [8A40]	[32]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of DTI-015 and Ocrelizumab.	Multiple sclerosis [8A40]	[33]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of DTI-015 and Ozanimod.	Multiple sclerosis [8A40]	[16]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of DTI-015 and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[34]
Gatifloxacin	DMSL679	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[17]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of DTI-015 and Canakinumab.	Rheumatoid arthritis [FA20]	[35]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of DTI-015 and Rilonacept.	Rheumatoid arthritis [FA20]	[35]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of DTI-015 and Golimumab.	Rheumatoid arthritis [FA20]	[36]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of DTI-015 and Leflunomide.	Rheumatoid arthritis [FA20]	[23]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of DTI-015 when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[37]
Cyclophosphamide	DM4O2Z7	Moderate	Decreased metabolism of DTI-015 caused by Cyclophosphamide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Cisplatin	DMRHGI9	Moderate	Decreased metabolism of DTI-015 caused by Cisplatin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of DTI-015 and Naltrexone.	Substance abuse [6C40]	[39]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of DTI-015 and Azathioprine.	Transplant rejection [NE84]	[13]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[17]
Enoxacin	DMYTE6L	Minor	Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[17]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of DTI-015 and Ganciclovir.	Virus infection [1A24-1D9Z]	[13]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of DTI-015 and Valganciclovir.	Virus infection [1A24-1D9Z]	[13]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Carmustine 100mg/vial injectable	100mg/vial	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800).
• [2] Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol). Neuro Oncol. 2007 Jan;9(1):12-9.
• [3] Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
• [4] Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia. 2003 Jan-Feb;5(1):9-16.
• [5] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [6] BDDCS applied to over 900 drugs
• [7] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol Histopathol. 2006 Nov;21(11):1199-207.
• [10] Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leuk Res. 1994 Nov;18(11):829-35.
• [11] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [12] Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006 Jan 10;24(2):274-87. doi: 10.1200/JCO.2005.02.9405. Epub 2005 Dec 19.
• [13] Cerner Multum, Inc. "Australian Product Information.".
• [14] Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
• [15] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [16] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [17] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [18] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [19] Bjornsson TD, Huang AT, Roth P, Jacob DS, Christenson R "Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations." Clin Pharmacol Ther 39 (1986): 25-8. [PMID: 3943266]
• [20] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [21] Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
• [22] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [23] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [24] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [25] Aguirre C, Rodriguez-Sasiain JM, Calvo R "Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents." Cancer Chemother Pharmacol 34 (1994): 86-8. [PMID: 8174208]
• [26] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [27] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [28] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [29] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [30] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [31] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [32] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [33] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [34] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [35] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [36] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [37] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [38] Fassas A, Gojo I, Rapoport A, et al. "Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy." Bone Marrow Transplant 28 (2001): 399-403. [PMID: 11571514]
• [39] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.